Edition:
United States

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

11.51USD
23 Feb 2018
Change (% chg)

$0.17 (+1.50%)
Prev Close
$11.34
Open
$11.43
Day's High
$11.51
Day's Low
$11.08
Volume
29,872
Avg. Vol
54,222
52-wk High
$17.11
52-wk Low
$4.63

Select another date:

Mon, Feb 12 2018

BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.

* SAVARA ANNOUNCES IND APPROVAL FOR EXPANSION OF MOLGRADEX PHASE 3 STUDY INTO U.S.

BRIEF-Savara ‍Received $5 Mln Award For Development Of Aerovanc​

* SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​ Source text for Eikon: Further company coverage:

BRIEF-Savara posts Q3 loss per share $0.28

* Savara reports third quarter 2017 financial results and provides business update

BRIEF-SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Savara announces proposed public offering of common stock

* Savara announces proposed public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Savara expands molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

* Savara announces expansion of molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

BRIEF-Savara reports completion of enrollment

* Savara reports completion of enrollment in phase 2 clinical trial of aironite for the treatment of hfpef

BRIEF-Savara announces start of pivotal Phase III AVAIL study of AeroVanc

* Savara announces start of pivotal Phase III AVAIL study of AeroVanc Source text for Eikon: Further company coverage:

BRIEF-Savara says entered into settlement agreement related to Serendex's acquisition

* Savara-On sept. 1, co, Serenova a/s entered into settlement agreement with respect to claim made by co related to Savara's acquisition of Serendex

Select another date: